▶ AMYLIN RECEPTOR AGONIST · SUBTOPIC · SAFETY PROFILE
AMYLIN RECEPTOR AGONIST Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of AMYLIN RECEPTOR AGONIST.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of AMYLIN RECEPTOR AGONIST. Severity, frequency, and attribution depend on the source publication.
- GI: nausea, vomiting (titration-dependent)
- Injection-site reactions
- Hypoglycemia risk when combined with insulin
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for AMYLIN RECEPTOR AGONIST.
- Insulin · additive hypoglycemia risk
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for AMYLIN RECEPTOR AGONIST in the published record:
- History of MTC or MEN2 (theoretical class effect)
FDA REGULATORY STATUS
Not yet FDA-approved as of 2026-05. Phase 3 REDEFINE program ongoing for CagriSema combination.
WADA REGULATORY STATUS
Not currently listed on the WADA Prohibited List.
SAFETY Q+A FROM LITERATURE
▶ How is the amylin receptor agonist different from pramlintide?
Pramlintide (Symlin) is the short-acting amylin analog FDA-approved 2005 for adjunctive use with insulin in type 1 and insulin-treated type 2 diabetes. the amylin receptor agonist is the long-acting analog with C20 fatty-acid albumin tether enabling once-weekly dosing for weight management.
▶ Is the amylin receptor agonist FDA-approved?
Not yet as of 2026-05. The Phase 3 REDEFINE program for CagriSema in obesity is ongoing.
▶ Side effects?
GI side effects (nausea, vomiting) are titration-dependent. Class precaution for MTC/MEN2 from preclinical thyroid C-cell observations.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Lau DCW, et al.. Once-weekly the amylin receptor agonist for weight management in people with overweight and obesity. Lancet 2021. PMID 34247670. link
- Frias JP, et al.. Efficacy and safety of co-administered once-weekly the amylin receptor agonist 2·4 mg with once-weekly the long-acting GLP-1 agonist 2·4 mg in type 2 diabetes. Lancet 2023. PMID 37364590. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19